mechlorethamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1647 | 51-75-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 15, 1949 | FDA | RECORDATI RARE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 445.23 | 52.66 | 80 | 1758 | 3904 | 63483280 |
| Application site pain | 363.89 | 52.66 | 68 | 1770 | 4114 | 63483070 |
| Application site erythema | 329.28 | 52.66 | 64 | 1774 | 4771 | 63482413 |
| Application site discolouration | 235.36 | 52.66 | 37 | 1801 | 784 | 63486400 |
| Application site irritation | 207.38 | 52.66 | 37 | 1801 | 1713 | 63485471 |
| Skin discolouration | 162.30 | 52.66 | 55 | 1783 | 37773 | 63449411 |
| Pruritus | 157.21 | 52.66 | 108 | 1730 | 361345 | 63125839 |
| Skin irritation | 144.09 | 52.66 | 37 | 1801 | 9704 | 63477480 |
| Erythema | 117.11 | 52.66 | 69 | 1769 | 175682 | 63311502 |
| Application site vesicles | 116.16 | 52.66 | 22 | 1816 | 1413 | 63485771 |
| Application site dryness | 105.14 | 52.66 | 15 | 1823 | 158 | 63487026 |
| Therapy non-responder | 96.63 | 52.66 | 46 | 1792 | 75855 | 63411329 |
| Skin burning sensation | 85.20 | 52.66 | 26 | 1812 | 12708 | 63474476 |
| Application site discharge | 81.15 | 52.66 | 12 | 1826 | 165 | 63487019 |
| Application site exfoliation | 69.85 | 52.66 | 12 | 1826 | 442 | 63486742 |
| Application site inflammation | 64.77 | 52.66 | 11 | 1827 | 378 | 63486806 |
| Skin hyperpigmentation | 61.40 | 52.66 | 17 | 1821 | 5904 | 63481280 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 478.45 | 55.30 | 81 | 1934 | 1356 | 34953560 |
| Application site erythema | 419.88 | 55.30 | 78 | 1937 | 2258 | 34952658 |
| Application site pain | 363.85 | 55.30 | 67 | 1948 | 1841 | 34953075 |
| Pruritus | 202.70 | 55.30 | 116 | 1899 | 141865 | 34813051 |
| Application site irritation | 188.87 | 55.30 | 33 | 1982 | 662 | 34954254 |
| Skin irritation | 178.19 | 55.30 | 45 | 1970 | 5532 | 34949384 |
| Application site vesicles | 172.15 | 55.30 | 30 | 1985 | 592 | 34954324 |
| Therapy non-responder | 139.93 | 55.30 | 60 | 1955 | 39086 | 34915830 |
| Erythema | 121.94 | 55.30 | 71 | 1944 | 88709 | 34866207 |
| Application site discolouration | 120.92 | 55.30 | 20 | 1995 | 284 | 34954632 |
| Skin burning sensation | 107.35 | 55.30 | 29 | 1986 | 4614 | 34950302 |
| Application site discharge | 96.07 | 55.30 | 15 | 2000 | 144 | 34954772 |
| Blister | 91.40 | 55.30 | 38 | 1977 | 22820 | 34932096 |
| Application site burn | 83.66 | 55.30 | 14 | 2001 | 214 | 34954702 |
| Skin discolouration | 82.74 | 55.30 | 33 | 1982 | 17812 | 34937104 |
| Cutaneous T-cell lymphoma | 77.81 | 55.30 | 18 | 1997 | 1520 | 34953396 |
| Second primary malignancy | 75.79 | 55.30 | 25 | 1990 | 7861 | 34947055 |
| Application site swelling | 74.05 | 55.30 | 13 | 2002 | 267 | 34954649 |
| Application site exfoliation | 73.66 | 55.30 | 12 | 2003 | 154 | 34954762 |
| Application site erosion | 71.08 | 55.30 | 11 | 2004 | 99 | 34954817 |
| Disease progression | 62.96 | 55.30 | 51 | 1964 | 108026 | 34846890 |
| Application site dryness | 58.15 | 55.30 | 9 | 2006 | 81 | 34954835 |
| Dermatitis | 56.30 | 55.30 | 21 | 1994 | 9447 | 34945469 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 914.85 | 43.92 | 158 | 3645 | 3652 | 79736933 |
| Application site erythema | 745.94 | 43.92 | 139 | 3664 | 4971 | 79735614 |
| Application site pain | 691.98 | 43.92 | 129 | 3674 | 4618 | 79735967 |
| Application site irritation | 402.20 | 43.92 | 70 | 3733 | 1674 | 79738911 |
| Application site discolouration | 334.05 | 43.92 | 54 | 3749 | 810 | 79739775 |
| Pruritus | 332.67 | 43.92 | 215 | 3588 | 394433 | 79346152 |
| Skin irritation | 301.82 | 43.92 | 76 | 3727 | 11164 | 79729421 |
| Application site vesicles | 273.33 | 43.92 | 49 | 3754 | 1391 | 79739194 |
| Therapy non-responder | 230.60 | 43.92 | 104 | 3699 | 92201 | 79648384 |
| Erythema | 220.59 | 43.92 | 135 | 3668 | 223155 | 79517430 |
| Skin discolouration | 219.62 | 43.92 | 80 | 3723 | 40954 | 79699631 |
| Skin burning sensation | 187.11 | 43.92 | 54 | 3749 | 13218 | 79727367 |
| Application site discharge | 171.92 | 43.92 | 27 | 3776 | 332 | 79740253 |
| Application site dryness | 159.25 | 43.92 | 24 | 3779 | 220 | 79740365 |
| Application site exfoliation | 120.02 | 43.92 | 21 | 3782 | 515 | 79740070 |
| Application site swelling | 119.29 | 43.92 | 22 | 3781 | 731 | 79739854 |
| Cutaneous T-cell lymphoma | 117.53 | 43.92 | 27 | 3776 | 2676 | 79737909 |
| Disease progression | 101.69 | 43.92 | 78 | 3725 | 184284 | 79556301 |
| Skin hyperpigmentation | 99.70 | 43.92 | 29 | 3774 | 7274 | 79733311 |
| Application site burn | 97.39 | 43.92 | 19 | 3784 | 856 | 79739729 |
| Application site erosion | 97.13 | 43.92 | 16 | 3787 | 270 | 79740315 |
| Application site inflammation | 95.65 | 43.92 | 17 | 3786 | 457 | 79740128 |
| Dermatitis | 93.59 | 43.92 | 36 | 3767 | 21285 | 79719300 |
| Blister | 92.12 | 43.92 | 62 | 3741 | 119414 | 79621171 |
| Application site rash | 91.10 | 43.92 | 21 | 3782 | 2111 | 79738474 |
| Dry skin | 90.31 | 43.92 | 50 | 3753 | 67945 | 79672640 |
| Application site reaction | 75.14 | 43.92 | 15 | 3788 | 761 | 79739824 |
| Application site scab | 72.48 | 43.92 | 12 | 3791 | 209 | 79740376 |
| Skin exfoliation | 71.72 | 43.92 | 40 | 3763 | 55060 | 79685525 |
| Second primary malignancy | 62.13 | 43.92 | 24 | 3779 | 14326 | 79726259 |
| Application site haemorrhage | 55.68 | 43.92 | 13 | 3790 | 1380 | 79739205 |
| Cutaneous T-cell lymphoma recurrent | 54.74 | 43.92 | 8 | 3795 | 58 | 79740527 |
| Scab | 54.17 | 43.92 | 20 | 3783 | 10552 | 79730033 |
| Lymphomatoid papulosis | 53.90 | 43.92 | 10 | 3793 | 343 | 79740242 |
| Skin reaction | 46.05 | 43.92 | 20 | 3783 | 16048 | 79724537 |
| Application site warmth | 45.45 | 43.92 | 8 | 3795 | 203 | 79740382 |
| Skin disorder | 45.12 | 43.92 | 25 | 3778 | 33918 | 79706667 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01AA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
| FDA MoA | N0000000236 | Alkylating Activity |
| FDA EPC | N0000175558 | Alkylating Drug |
| MeSH PA | D000477 | Alkylating Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
| MeSH PA | D002619 | Chemical Warfare Agents |
| MeSH PA | D007509 | Irritants |
| MeSH PA | D009676 | Noxae |
| MeSH PA | D011042 | Poisons |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic lymphoid leukemia, disease | indication | 92814006 | |
| Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
| Polycythemia vera | indication | 109992005 | |
| Hodgkin's disease | indication | 118599009 | |
| Non-Hodgkin's lymphoma | indication | 118601006 | |
| Mycosis fungoides | indication | 118618005 | |
| Malignant tumor of lung | indication | 363358000 | |
| Primary cutaneous T-cell lymphoma | indication | 400122007 | |
| Pericardial Malignant Effusions | indication | ||
| Peritoneal Malignant Effusions | indication | ||
| Pleural Malignant Effusions | indication | ||
| Amyloidosis | contraindication | 17602002 | DOID:9120 |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Acute infectious disease | contraindication | 63171007 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Secondary malignant neoplasm of bone marrow | contraindication | 94217008 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Chemotherapy-Induced Hyperuricemia | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.7 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 8501819 | March 7, 2026 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 7872050 | July 8, 2029 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4019808 | VUID |
| N0000147897 | NUI |
| D04872 | KEGG_DRUG |
| 55-86-7 | SECONDARY_CAS_RN |
| 4017994 | VANDF |
| 4019808 | VANDF |
| C0025033 | UMLSCUI |
| CHEBI:28925 | CHEBI |
| CHEMBL427 | ChEMBL_ID |
| DB00888 | DRUGBANK_ID |
| CHEMBL1201001 | ChEMBL_ID |
| D008466 | MESH_DESCRIPTOR_UI |
| 4033 | PUBCHEM_CID |
| 586 | INN_ID |
| 7218 | IUPHAR_LIGAND_ID |
| 50D9XSG0VR | UNII |
| 155036 | RXNORM |
| 1972 | MMSL |
| 29634 | MMSL |
| 5028 | MMSL |
| d01339 | MMSL |
| 002630 | NDDF |
| 004816 | NDDF |
| 29156002 | SNOMEDCT_US |
| 372692002 | SNOMEDCT_US |
| 387071000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |
| VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |